BIOLOGICAL · Unmapped registry intervention
ramucirumab (IMC-1121B)
Find medicine records ·
Find other trials using this name
Clinical trial
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
NCT00703326
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
docetaxel
Normalized identity: docetaxelView linked drug · Find medicine records ·
Find other trials using this name
OTHER · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedPhase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00703326 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.